公开(公告)号：EP1537075B1

公开(公告)日：2009-07-01

申请号：EP03793605.1

申请日：2003-09-04

申请人： NeuroSearch A/S

发明人： DAHL, Bjarne, H. ,  CHRISTOPHERSEN, Palle ,  ENGSIG, Michael, Thyrring ,  KARSDAL, Morten, Asser ,  FOGED, Niels, T kker ,  JENSEN, Flemming, Reissig

IPC分类号： C07C275/26 ,  C07C275/28 ,  C07D257/04 ,  C07D207/00 ,  A61K31/17 ,  A61K31/41 ,  A61P19/00 ,  A61P43/00

CPC分类号： C07D213/75 ,  C07C275/26 ,  C07C275/30 ,  C07C275/42 ,  C07C2601/14 ,  C07D207/16 ,  C07D209/40 ,  C07D213/81 ,  C07D231/40 ,  C07D257/04 ,  C07D277/48 ,  C07D295/192 ,  C07D307/68 ,  C07D333/36 ,  C07D401/12 ,  C07F9/383 ,  C07F9/3834 ,  C07F9/3882 ,  C07F9/582 ,  C07F9/587

摘要： The present invention relates to novel diarylurea derivatives represented by general formula (I) useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of bone metabolic diseases, diseases responsive to modulation of the mast cell or basophil activity, diseases responsive to inhibition of angiogenesis, or sickle cell anaemia, and to pharmaceutical compositions comprising the compounds of the invention.

摘要翻译： 本发明涉及可用作氯化物通道阻断剂的新型二芳基脲衍生物。 在其他方面，本发明涉及这些化合物在治疗方法中的用途，例如用于治疗骨代谢疾病，对调节肥大细胞或嗜碱性粒细胞活性有响应的疾病，对抑制血管生成有响应的疾病或镰状细胞 贫血，以及包含本发明化合物的药物组合物。

公开(公告)号：EP1537075A2

公开(公告)日：2005-06-08

申请号：EP03793605.1

申请日：2003-09-04

申请人： NEUROSEARCH A/S

发明人： DAHL, Bjarne, H. ,  CHRISTOPHERSEN, Palle ,  ENGSIG, Michael, Thyrring ,  KARSDAL, Morten, Asser ,  FOGED, Niels, T kker ,  JENSEN, Flemming, Reissig

IPC分类号： C07C275/26 ,  C07C275/28 ,  C07D257/04 ,  C07D207/00 ,  A61K31/17 ,  A61K31/41 ,  A61P19/00 ,  A61P43/00

CPC分类号： C07D213/75 ,  C07C275/26 ,  C07C275/30 ,  C07C275/42 ,  C07C2601/14 ,  C07D207/16 ,  C07D209/40 ,  C07D213/81 ,  C07D231/40 ,  C07D257/04 ,  C07D277/48 ,  C07D295/192 ,  C07D307/68 ,  C07D333/36 ,  C07D401/12 ,  C07F9/383 ,  C07F9/3834 ,  C07F9/3882 ,  C07F9/582 ,  C07F9/587

摘要： The present invention relates to novel diarylurea derivatives represented by general formula (I) useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of bone metabolic diseases, diseases responsive to modulation of the mast cell or basophil activity, diseases responsive to inhibition of angiogenesis, or sickle cell anaemia, and to pharmaceutical compositions comprising the compounds of the invention.